Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
-
New hope for cancer survivors: drug aims to shield against Life-Threatening infections
Disease control Not yet recruitingThis study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to calm inflammation in kidney dialysis patients
Disease control Not yet recruitingThis early-stage trial tests a drug called CSL300 (clazakizumab) in 24 Chinese adults with end-stage kidney disease who are on dialysis. The drug is an antibody that blocks interleukin-6, a protein involved in inflammation. The main goal is to see how the drug moves through the b…
Phase: PHASE1 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a higher dose slow lung damage in Alpha-1 patients?
Disease control Not yet recruitingThis study tests whether higher doses of the drug Respreeza/Zemaira can slow lung damage better than the standard dose in adults with emphysema caused by Alpha-1 antitrypsin deficiency. About 270 participants will receive weekly IV infusions for 3 years. The goal is to find the o…
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC